Physiological and medical responses to anabolic-androgenic steroids: Review;Anabolik-androjenik steroidlere karşi fizyolojik ve tibbi yanitlar

Turkiye Klinikleri Journal of Medical Sciences

Volumn 28, Issue 6, 2008, Pages 923-932

  Özdemir, Ercan ^a   Gültürk, Sefa ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Androgens; Muscle; Skeletal; Sports

Indexed keywords

ANABOLIC AGENT; METHYLTESTOSTERONE; NANDROLONE PHENPROPIONATE; OXANDROLONE; OXYMETHOLONE; STANOZOLOL; TESTOSTERONE; TESTOSTERONE DERIVATIVE;

ATHEROSCLEROSIS; ATHLETE; BEHAVIOR; BLOOD PRESSURE; CARDIOMYOPATHY; DOSE RESPONSE; DRUG ABUSE; DRUG SAFETY; ENDURANCE; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCOAGULABILITY; IMPOTENCE; LEAN BODY WEIGHT; LIBIDO; LIVER DYSFUNCTION; MASCULINITY; MUSCLE HYPERTROPHY; MUSCLE STRENGTH; PSYCHOPATHY; REVIEW; SIDE EFFECT; SKIN DISEASE; SPORT; SUBFERTILITY; TESTIS ATROPHY; THROMBOSIS;

EID: 60249098506     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Yesalis CE, Kennedy NJ, Kopstein AN, Bahrke MS. Anabolic-androgenic steroid use in the United States. JAMA 1993;270:1217-21.
2. National Institute on Drug Abuse. About anabolic steroid abuse. NIDA notes 2000;15:15.
3. Evans NA. Gym and tonic: a profile of 100 male steroid users. Br J Sports Med 1997;31:54-8.
4. A. Vermeulen androgen replacement therapy in the aging male - a critical evaluation. J Clin Endocrinol Metab 2001;86:2380-90.
5. Bhasin S, Storer TW, Berman n, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fatfree mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-13.
6. Yesalis C, Wright J, Lombardo J. Anabolic-androjenic steroids: a synthesis of existing data and recommendations for furhter research. Clinical Sports Medicine 1989;1:109-34.
7. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:55-69.
8. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997;43:1262-79.
9. Loughton SJ, Ruhling RO. Human strength and endurance responses to anabolic steroid and training. J Sports Med Phys Fitness 1977;17:285-96.
10. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem 1996;42:1001-20.
11. Perry HM, Wright D, Littlepage bn. Dying to be big: a review of anabolic steroid use. Br J Sports Med 1992;26:259-61.
12. Wilson JD. Androgens. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's Experimental Basis of Therapeutics. New York, NY: McGraw-Hill; 1996. p.1441-57.
13. Bardin CW. The anabolic action of testosterone. N Engl J Med 1996;335:52-3.
14. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-53.
15. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984;12:469-84.
16. Vardar E, Vardar SA, Tuǧlu C. Anabolik-androjenik steroidlerin köt-dsuye kullanimi Anadolu Psikiyatri Dergisi 2002;3:104-7.
17. Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002;57:411-34.
18. Bhasin S, Bremner WJ. Clinical review 85: Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 1997;82:3-8.
19. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med 2004;32:534-42.
20. Inoue K, Yamasaki S, Fushiki T, okada Y, Sugimoto E. Androgen receptor antagonist suppresses exercise-induced hypertrophy of skeletal muscle. Eur J Appl Physiol occup Physiol 1994;69:88-91.
21. Carson JA, Lee WJ, McClung J, Hand GA. Steroid receptor concentration in aged rat hindlimb muscle: effect of anabolic steroid administration. J Appl Physiol 2002;93:242-50.
22. Bamman MM, Shipp JR, Jiang J, Gower BA, Hunter GR, Goodman A, et al. Mechanical load increases muscle IGF-I and androgen receptor mRnA concentrations in humans. Am J Physiol Endocrinol Metab 2001;280:E383-90.
23. Yates WR. Testosterone in Psychiatry: Risks and Benefits Arch Gen Psychiatry 2000;57:155-6.
24. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry 1996;153:974-84.
25. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993;269:2760-4.
26. Haupt HA. Anabolic steroids and growth hormone. Am J Sports Med 1993;21:468-74.
27. Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon Dn, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999;84:2705-11.
28. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269(5 Pt 1):E820-6.
29. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol. Endocrinol Metab 2001;281:E1172-81.
30. Özdemir E, Erdal S, Gültürk, S, Ciçan diyafragma kasinda kortikosteroidlerin olusturduǧu deǧişiklilderin anabolik steroidlerie geri döndürülmesi C. U. Tip Fakültesi Dergisi 2003; 25:105-10.
31. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2002;283:E154-64.
32. Brodsky IG, balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996;81:3469-75.
33. Ferrando AA, Tipton KD, Doyle D, Phillips SM, Cortiella J, Wolfe RR. Testosterone injection stimulates net protein synthesis but not tissue amino acid transport. Am J Physiol. 1998;275(5 Pt 1):E864-71.
34. Tamaki T, Uchiyama S, Uchiyama Y, Akatsuka A, Roy RR, Edgerton VR. Anabolic steroids increase exercise tolerance. Am J Physiol Endocrinol Metab 2001;280:E973-81.
35. Falanga V, Greenberg AS, Zhou L, Ochoa SM, Roberts AB, Falabella A, et al. Stimulation of collagen synthesis by the anabolic steroid stanozolol. J Invest Dermatol 1998;111:1193-7.
36. Al-Ismail K, Torreggiani WC, Munk PL, nicolaou S. Gluteal mass in a bodybuilder: radiological depiction of a complication of anabolic steroid use. Eur Radiol 2002;12:1366-9.
37. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886-92.
38. Bhasin S, Storer TW, Berman n, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7.
39. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160:105-11.
40. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998;48:157-61.
41. Bhasin S, Storer TW, Javanbakht M, berman n, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000;283:763-70.
42. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 2000;133:348-55.
43. Rabkin JG, Wagner GJ, Rabkin R. A doubleblind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000;57:141-7.
44. Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks Jb, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002;87:5649-57.
45. Bross R, Javanbakht M, Bhasin S. Anabolic interventions for aging-associated sarcopenia. J Clin Endocrinol Metab 1999;84:3420-30.
46. Schroeder ET, Singh A, Bhasin S, Storer TW, Azen C, Davidson T, et al. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Am J Physiol Endocrinol Metab 2003;284:E120-8.
47. Evans NA. Local complications of self administered anabolic steroid injections. Br J Sports Med 1997;31:349-50.
48. Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes. A case series analysis. Am J Sports Med 1990;18:422-8.
49. Pope HG Jr, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry 1994;51:375-82.
50. Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction 2002;97:195-203.
51. Street C, Antonio J, Cudlipp D. Androgen use by athletes: a reevaluation of the health risks. Can J Appl Physiol 1996;21:421-40.
52. Sattler FR, Jaque SV, Schroeder ET, olson C, Dube MP, Martinez C, et al. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 1999;84:1268-76.
53. Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: a review for the clinician. Sports Med 2002;32:285-96.
54. Pärssinen M, Seppälä T. Steroid use and long-term health risks in former athletes. Sports Med 2002;32:83-94.
55. Furlanello F, Serdoz LV, Cappato R, De Ambroggi Llllicit drugs and cardiac arrhythmias in athletes. Eur J Cardiovasc Prev Rehabil 2007;14:487-94.
56. Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol 2007;5:809-12.
57. Scott MJ 3rd, Scott AM. Effects of anabolicandrogenic steroids on the pilosebaceous unit. Cutis 1992;50:113-6.
58. Shuster S. The cause of striae distensae. Acta Derm Venereol Suppl (Stockh) 1979;59: 161-9.
59. Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med 1990;18:429-31.
60. Lloyd FH, Powell P, Murdoch AP. Anabolic steroid abuse by body builders and male subfertility. BMJ 1996;313:100-1.
61. Boyadjiev NP, Georgieva KN, Massaldjieva RI, Gueorguiev SI. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. J Sports Med Phys Fitness 2000;40:271-4.
62. Turek PJ, Williams RH, Gilbaugh JH 3rd, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. J Urol 1995;153: 1628-30.
63. Gill GV. Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J 1998;74:45-6.
64. Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. JAMA 1985;253:2871-3.
65. Bahrke MS, Yesalis CE 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med 1996;22:367-90.
66. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep 2002;4:377-87.
67. Brower KJ. Withdrawal from anabolic steroids. Curr Ther Endocrinol Metab 1997;6:338-43.
68. Melchert Rb, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc 1995;27:1252-62.
69. Graham MR, Grace FM, Boobier W, Hullin D, Kicman A, Cowan D, et al. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med 2006;40:644-8.
70. Pärssinen M, Kujala U, Vartiainen E, Sama S, Seppälä T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000;21:225-7.
71. Bryden AA, Rothwell PJ, O'Reilly PH. Anabolic steroid abuse and renal-cell carcinoma. Lancet 1995;346:1306-7.
72. Froehner M, Fischer R, Leike S, Hakenberg OW, Noack B, Wirth MP. Intratesticular leiomyosarcoma in a young man after high dose doping with Oral-Turinabol: a case report. Cancer 1999;86:1571-5.
73. Evans NA. Spotting steroid use: which physical clues? Phys Sports Med 2003;31:18.
74. Evans NA, Bowrey DJ, Newman GR. Ultrastructural analysis of ruptured tendon from anabolic steroid users. Injury 1998;29:769-73.